Gut Microbiota‑Mediated Arsenic Metabolism Research

Gut Microbiota‑Mediated Arsenic Metabolism Research Service – From Speciation Analysis to Functional Pathway Mapping

You are searching for gut microbiota and arsenic metabolism research because you need to perform this study—whether to elucidate how commensal bacteria transform arsenic species, identify microbial genes responsible for arsenic methylation or volatilisation, assess host absorption of microbially‑modified arsenic, or evaluate probiotic interventions for arsenic detoxification. We provide a complete research service that combines anaerobic in vitro fermentation, isotope‑tracing, multi‑omics profiling (metagenomics, metatranscriptomics, metabolomics), and in vivo vertebrate models to deliver a mechanistic understanding of gut microbiome‑driven arsenic biotransformation.

What We Detect – Arsenic Speciation, Microbial Metabolites & Functional Gene Inventory

Our gut‑microbiota arsenic metabolism service goes far beyond measuring total arsenic in faeces. Using high‑performance liquid chromatography coupled with inductively coupled plasma mass spectrometry (HPLC‑ICP‑MS) and hyphenated HPLC‑ESI‑Q‑TOF‑MS, we quantify 10 arsenical species including inorganic arsenite (As^III), arsenate (As^V), monomethylarsonic acid (MMA^III/V), dimethylarsinic acid (DMA^V), trimethylarsine oxide (TMAO), tetramethylarsonium (TETRA), arsenobetaine (AsB), arsenocholine, and volatile arsines (by cryotrapping GC‑ICP‑MS) with detection limits of 0.05‑0.2 µg/L per species. We simultaneously profile short‑chain fatty acids (SCFAs: acetate, propionate, butyrate, valerate) by GC‑FID and sulphur‑containing metabolites (glutathione, cysteine, hydrogen sulfide) by LC‑MS/MS – key modulators of arsenic redox state. For the microbial community, we perform deep shotgun metagenomic sequencing (50 million reads per sample, 150 bp PE) to assemble arsenic biotransformation gene clusters (arsC, arsB, arrA, arsM, arsI, arsP, arsR) and quantify their abundance at strain‑level resolution (bins). Our metatranscriptomics (rRNA‑depleted RNA‑seq) reveals which microbial phylotypes are transcriptionally active in arsenic transformation under different gut conditions.

How Deep We Go – Dynamic In Vitro Gut Models, In Vivo Tracing & Mechanistic Validation

We don't just report species correlations. Our advanced pipeline includes customised anaerobic continuous culture systems (TIM‑2, SHIME®, or single‑stage chemostats) that mimic human distal gut conditions (pH 6.0‑6.8, temperature 37°C, residence time 24‑72 h, controlled redox potential <‑300 mV). Using ⁷³As‑radiolabelled or stable isotope ⁷⁷As‑spiked substrates, we perform mass balance and flux analysis to determine rates of methylation (nmol/g/h), reduction (As^V→As^III), and volatilisation (arsine capture) by individual donor microbiota. We also establish gnotobiotic mouse models (colonised with defined human gut consortia or specific arsenic‑metabolising isolates) to track systemic arsenic absorption, tissue distribution (liver, kidney, bladder), and urinary excretion profile – linking microbial metabolism to host pharmacokinetics. For mechanistic validation, we isolate and culture strict anaerobic arsenic‑transforming bacteria (e.g., Clostridium, Faecalibacterium, Desulfovibrio species) from faecal samples and perform targeted gene knockout/complementation (using ClosTron or allelic exchange in anaerobes) to assign function to candidate arsM or arsC alleles. Our transcriptomic analysis of host intestinal epithelium (laser‑capture microdissection of ileal/colonic crypts) after arsenic exposure assesses tight junction integrity (ZO‑1, occludin, claudin), inflammation (IL‑6, TNF‑α, IL‑10), and oxidative stress (Nrf2, HO‑1, GPx) – connecting microbial arsenic metabolites to host response.

Why Our Gut Arsenic Metabolism Research Stands Out – Complete Anaerobic Workflow, Multi‑Isotope Tracing & Clinical Relevance

1. Dedicated anaerobic sample handling: From collection (pre‑reduced anaerobic transport medium) to culture and species extraction, all steps are performed in anaerobic chambers (85% N₂, 10% CO₂, 5% H₂, <1 ppm O₂) – preserving native arsenic speciation and viable oxygen‑sensitive metabolisers.
2. Comprehensive arsenic speciation including volatile species: We are one of few labs offering cryotrapping GC‑ICP‑MS for arsine, monomethylarsine, and dimethylarsine (LOQ 0.02 ng As). This allows complete closure of arsenic mass balance in fermentation systems.
3. Strain‑level resolution of arsenic biotransformation potential: Using long‑read metagenomics (Nanopore or PacBio HiFi) we resolve complete ars operon structures and link them to specific bacterial genomes – not just contigs. This has identified novel arsM methyltransferases in previously uncultured Firmicutes.
4. Quantification of flux, not just abundance: We provide rate constants (k_methylation, k_reduction, k_{volatilisation}) per gram of faecal inoculum or per defined community – essential for physiologically based pharmacokinetic (PBPK) modelling.
5. Human relevance & clinical support: We have processed over 500 human faecal samples from arsenic‑exposed populations (Bangladesh, Chile, USA) and built a reference database of 120 metagenome‑assembled genomes (MAGs) containing complete ars operons. Our reports have supported three NIH R01 projects and one EPA STAR grant.

Who Relies on Our Gut Arsenic Metabolism Research – Real‑World Impact

A research group studying arsenic‑induced carcinogenesis used our gnotobiotic mouse model with defined human gut microbiota to show that presence of arsM‑positive Clostridium species increased urinary DMA^V by 8‑fold and significantly reduced bladder tissue arsenic levels – suggesting a protective role. Another team investigating probiotic mitigation of arsenic toxicity sent us faecal samples from a clinical trial of Lactobacillus rhamnosus GG; our ex vivo fermentation with ⁷³As revealed a 40% increase in arsenic methylation rate after probiotic intervention, correlating with lower blood arsenic in participants. A environmental health laboratory used our continuous culture SHIME® model to test the effect of dietary fibre on arsenic biotransformation – they discovered that inulin selectively promoted arsC‑ and arsM‑expressing Bifidobacterium strains, doubling the conversion of inorganic arsenic to less toxic DMA. A biotechnology company developing engineered arsenic‑detoxifying bacteria validated their construct in our anaerobic faecal fermenter – we tracked survival of the strain (by qPCR of plasmid marker) and increased total volatile arsine production (by GC‑ICP‑MS) by 15‑fold over background.

Ready to Start Your Gut Microbiota & Arsenic Metabolism Study?

Send us fresh faecal samples (≥5 g, collected in anaerobic transport medium), faecal slurries, or frozen pellets (≥200 mg) – human, mouse, or other species. We can also accept cecal contents, colonic biopsies, or defined microbial consortia. We will perform anaerobic incubations with spiked arsenic species (As^III, As^V, or your test compound), full speciation at multiple timepoints, metagenomic/metatranscriptomic profiling, flux calculations, and optional host model studies – delivering a comprehensive report within 4‑8 weeks depending on experimental depth. Request a free consultation; we will design the optimal study (static batch, continuous culture, gnotobiotic, or clinical sample biobanking) for your mechanistic or translational question.